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Introduction
Among the various procedures proposed
for use in assessing the mutagenic potential
of drugs, the dominant-lethal (D-L) assay
stands currently as one of the few tests for
measuring mutagenic effects on germ cells.
Early identification of the D-L assay as a
possible member of a test battery relates
strongly to its being a mammalian model.
Many scientists within the pharmaceutical
industry believe that only those tests which
utilize a mammalian model should be con-
sidered for primary use in drug safety
evaluation protocols. The reason for such
belief is obvious when one considers that the
entire process of drug safety evaluation is
oriented on established concepts in phar-
macology and toxicology. Mammalian pro-
cesses of assimilation, absorption, distribu-
tion, metabolism and elimination must be
permitted to work on the chemical under
test in order to provide some basis for ex-
trapolating mutagenicity test data to man
(1). Dose levels tested in these models and
routes of drug administration should both
reflect human use. Also, differences in the
qualitative pharmacologic action of drugs
must be considered as an essential part of
the criteria applied to dose selection. Test
reproducibility and dose-effect relationships
*Medical Research Laboratories, Pfizer Central
Research, Groton, Connecticut 06340.
must be emphasized in mutagenicity studies
in order to identify those levels at which
any mutagenic action is first detectable and
to relate this level to the dose required for
therapeutic efficacy.
In this presentation, data have been
selected from a number of D-L studies which
relate to these points and the difficulties
encountered in interpreting D-L test results.
Methods
Random-bred CD-1 mice (Charles River),
8 weeks of age, were used in all experi-
ments except where noted. Generally, 15
males were assigned to each test and control
group, and 2 females were caged with each
male. Pregnant females were identified by
the presence of a mating plug. The number
of total and dead implants/pregnant female
were determined by autopsy at 12-14 days
of pregnancy. Statistical analyses were com-
puterized and all tests of significance were
performed on arcsine transformed data.
Weekly summations of test data were com-
pared to a control regression computed
across the entire 8 weeks of testing (2).
These statistical models are discussed in the
paper by Dr. David Salsburg (3).
Results and Discussion
Strain Characterization
Continuous surveillance of the mouse
December 1973 27Table 1. Dominant-lethal assay: historical control, CD-1 strain, March 1971 through March 1973.
Week Number Dead Total
Tot. impl. Dead impl. Live impl. % Dead
pregnant Embryos implants implants preg. fem. preg. fem. preg. fem. impl.
1 871 9,880 745 10,625 12.20 0.86 11.34 7.0
2 1,009 11,499 884 12,383 12.27 0.88 11.40 7.1
3 966 11,228 823 12,051 12.48 0.85 11.62 6.8
4 901 10,360 830 11,190 12.42 0.92 11.50 7.4
5 863 10,100 749 10,849 12.57 0.87 11.70 6.9
6 745 8,869 667 9,536 12.80 0.90 11.90 7.0
7 718 8,463 631 9,094 12.67 0.88 11.79 6.9
8 747 8,680 703 9,383 12.56 0.94 11.62 7.5
strain selected for use in the D-L assay is an
absolute necessity. Spurious increases in the
number of dead implants/pregnant female,
or a reduction in the total implants/pregnant
female of the control group can have such a
marked effect on determinations of domi-
nant lethality that both these parameters
must be monitored continuously. Strains
that have high levels of fetal wastage due
to genetic factors or infectious disease bur-
dens are not well suited to use in the D-L
assay.
Control data on 6820 pregnant females
(CD-1 strain) are presented in Table 1. All
data are expressed as a function of the week
of mating following treatment of the male.
The control males mated with these females
had received physiological saline. This strain
has consistently maintained an average level
of total implants/pregnant female close to
12.50. The average number of dead implants/
pregnant female is 0.89 and the average of
living implants/pregnant female is 11.61.
When the number of dead implants is com-
pared to the total implants an average value
of 7.1% is obtained.
An example of a shift in the reproduc-
tive behavior of this strain is shown in
Table 2. During the period of November 1,
1972 to March 1, 1973 the number of dead
implants/pregnant female rose to a value of
1.02. This was accompanied by a reduction
in the number of living implants/pregnant
female to 11.43. Total implants/pregnant
female was 12.38 and the percent dead
implants/total implants was 8.2. Although
such a shift may appear slight, this degree
of fetal wastage can produce problems in
the interpretation of test results and reduce
the sensitivity of the test (4). The rapid
rise observed in this period suggests the
introduction of an infectious disease entity
although no overt clinical disease was evid-
ent.
Occasionally, a genetically aberrant male
is encountered which produces a D-L effect
in several stages of spermatogenesis. Table
3 shows such a result with significant re-
sponses in weeks 1 through 7. The compound
involved normally produces a D-L effect in
weeks 5 and 6. Additional analyses revealed
a single male had produced this response.
Test Reproducibility
A true mutagenic response in the D-L
assay can be characterized by a statistically
significant increase in dead implants/preg-
nant female accompanied by a statistically
significant reduction in living implants/
pregnant female. Additionally, the compound
involved should show a dose response rela-
tionship during a specific stage in the sper-
matogenic cycle. If a statistically significant
response cannot be demonstrated reproduc-
ibly in the same stage of spermatogenesis,
then a spurious positive result should be
suspected. Table 4 demonstrates the typical
response of the mutagen, ethyl methane-
sulfonate. In both experiments, the number
of dead implants/pregnant female increases
markedly during the first two weeks of
mating. It should be noted that a significant
decrease in the number of living implants
per pregnant female occurs in the same two
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FIGURE 1. EMS dose response: days 7 through 11 post-injection.
weeks. A dose-response curve is shown in
Figure 1 for the period 7-11 days following
mating (5).
Another example of a reproducible D-L
effect is depicted in Table 5. The purine
analog, 6-mercaptopurine has produced a
consistent D-L effect during weeks 5 and 6
of the spermatogenic cycle (6). Again, the
parameter of living implants/pregnant fe-
male showed a simultaneous and significant
reduction.
Nonreproducible Results
In contrast to the reproducibility obtainedl
Table 2. Dominant-lethal assay: historical control, CD-1 strain, November 1, 1972-March 1, 1973.
Tot. impl. Dead impl. Live impl. Number Dead Total toc Dead
Week pregnant Embryos implants implants Preg. fem. Preg. fem. Preg. fem. impl.
1 148 1684 128 1812 12.24 0.86 11.38 7.06
2 163 1891 155 2046 12.55 0.95 11.60 7.58
3 166 1853 161 2014 12.13 0.97 11.16 7.99
4 156 1808 172 1980 12.69 1.10 11.59 8.69
5 156 1808 154 1962 12.58 0.99 11.59 7.85
6 129 1505 133 1638 12.70 1.03 11.67 8.12
7 122 1387 115 1502 12.31 0.94 11.37 7.66
8 98 1086 127 1213 12.38 1.30 11.08 10.47
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Number Total Tot. impl. Dead impl. Live impl.
Week pregnant implants Preg. fem. Preg. fem. Dead impl. Preg. fem.
C T C T C T C T C T C T
1 b 26 34 319 375 12.3 11.0 0.65 1.24 5.3 11.2 11.6 9.8
2 b 43 46 535 586 12.4 12.7 1.19 1.32 9.5 10.4 11.3 11.4
3 b 39 47 460 612 11.8 13.0 0.62 1.26 5.2 9.6 11.2 11.8
4 b 34 47 435 619 12.8 13.2 0.79 1.38 6.2 10.5 12.0 11.8
5 b 41 47 498 594 12.1 12.6 1.17 1.79 9.6 14.1 11.0 10.9
6 b 28 29 360 338 12.9 11.7 1.07 2.28 8.3 19.5 11.8 9.4
7 b 44 41 563 516 12.8 12.6 1.11 1.63 8.7 13.0 11.7 11.0
8 48 27 623 343 13.0 12.7 0.97 1.41 7.5 11.1 12.0 11.3
a C denotes controls; T denotes treated animals.
b Significance at the 1% level (dead implants/pregnant females).
during the same stage of spermatogenesis weeks 2 and 4. It should be noted that the
with a true mutagen, spurious or false- parameter of living implants/pregnant fe-
positive results do not repeat during the same male was not significantly reduced.
stage of spermatogenesis. An example of this Tables 7-12 show the kind of inconsisten-
kind of results is shown in Table 6. The com- cies which may occur in the dominant-lethal
pound produced effects on two separate assay with a nonmutagenic substance. The
stages of spermatogenesis in the first two response at week 7 at a dose of 7.5 mg/kg
experiments. A third experiment performed (Table 8) was not reproduced at a level of 75
at the same dose level was negative in both mg/kg (Table 10). Further, the response
Table 4. Example of a reproducible result in the dominant-lethal assay with ethyl
methanesulfonate, 300 mg/kg, oral.
Number Total Tot. impl. Dead impl.
0 Live impl.
Week pregnant implants Preg. fem. Preg. fem. Dead impl. Preg. fem.
C T C T C T C T C T C T
1 a 58 43 704 488 12.14 11.35 1.12 1.81 9.23 15.98 11.02 9.53
2a 51 54 657 588 12.88 10.89 1.06 3.26 8 22 29.93 11.82 7.63
3 56 36 763 457 13.62 12.69 1.09 0.86 7.99 6.78 12.54 11.83
4 28 37 379 468 13.54 12.65 0.90 0.89 7.12 7.05 12.57 11.76
5 34 29 496 385 14.59 13.28 1.41 0.76 9.68 5.71 13.18 12.52
6 40 33 579 475 14.48 14.39 1.30 0.97 8.98 6.74 13.17 13.42
7 41 25 550 314 13.41 12.56 0.76 0.76 5.64 6.05 12.66 11.80
8 31 37 427 455 13.77 12.30 1.26 0.95 9.13 7.69 12.52 11.35
1a 32 42 379
2 40 26 481
3 46 43 576
4 51 38 648
5 39 27 510
6 37 14 506
7 33 16 464
8 28 20 358
473 11.84 11.26
312 12.02 12.00
511 12.52 11.88
491 12.71 12.92
353 13.08 13.07
199 13.68 14.21
224 14.06 14.00
274 12.79 13.70
0.84 2.86 7.12 25.37 11.00 8.40
1.30 3.23 10.81 26.92 10.73 8.77
1.13 1.07 9.03 9.00 11.39 10.81
0.92 0.76 7.25 5.91 11.78 12.16
1.05 0.96 8.04 7.37 12.03 12.11
1.11 1.14 8.10 8.04 12.57 13.07
1.12 0.81 7.97 5.80 12.94 13.19
0.96 1.05 7.54 7.66 11.82 12.65
a Significance at the 1% level (dead implants/pregnant female).
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6-mercaptopurine, 150 mg/kg, IP.
Number Total Tot. impl. Deadimpl. 0
Liveimpl.
Week pregnant implants Preg. fem. Preg. fem. Dead impl. Preg. fem.
C T C T C T C T C T C T
1 26 33 319
2 43 38 535
3 39 43 460
4 34 52 435
5 41 34 498
6 28 24 360
7 44 28 563
8 48 37 623
1 41 42 528
2 35 36 438
3 45 50 577
4 44 48 557
5a 40 40 536
6 a 38 49 500
7 43 41 560
8 42 38 542
411
470
553
665
408
284
329
465
511
452
635
606
487
610
526
500
12.3
12.4
11.8
12.8
12.1
12.9
12.8
13.0
12.9
12.5
12.8
12.7
13.4
13.2
13.0
12.9
12.5 0.65 0.67
12.4 1.19 1.05
12.9 0.62 0.79
12.8 0.79 0.96
12.0 1.17 2.24
11.8 1.07 2.50
11.8 1.11 0.89
12.6 0.97 1.14
12.2 0.71 0.98
12.6 0.74 1.00
12.7 0.82 0.44
12.6 0.89 0.65
12.2 0.83 2.10
12.4 0.97 1.73
12.8 0.49 0.78
13.2 0.62 0.89
5.3 5.4 11.6 11.8
9.5 8.5 11.3 11.3
5.2 6.2 11.2 12.1
6.2 7.5 12.0 11.8
9.6 18.6 11.0 9.8
8.3 21.1 11.8 9.3
8.7 7.6 11.7 10.9
7.5 9.0 12.0 11.4
5.5 8.0 12.2 11.2
5.9 8.0 11.8 11.6
6.4 3.5 12.0 12.3
7.0 5.1 11.8 12.0
6.2 17.3 12.6 10.1
7.4 13.9 12.2 10.7
3.8 6.1 12.5 12.0
4.8 6.8 12.3 12.3
a Significance at the 1% level (dead implants/pregnant female).
Table 6. Example of a nonreproducible result in the dominant-lethal assay,
experiment 50, dose 12 mg/kg, oral.
Number Total Tot. impl. Dead impl. __Live impl.
Week pregnant implants Preg. fem. Preg. fem. Dead impl. Preg. fem.
C T C T C T C T C T C T
1 39 35 470
2' 39 45 510
3 35 41 438
4 34 34 436
5 39 35 496
6 40 41 490
7 37 38 464
8 23 25 284
1 38 32 363
2 46 45 540
3 39 48 472
4 a 49 32 671
5 28 32 387
6 31 28 429
7 27 29 353
8 31 24 404
461 12.05 13.17
613 13.08 13.62
557 12.51 13.59
434 12.82 12.76
446 12.72 12.74
486 12.25 11.85
471 12.54 12.39
333 12.35 13.32
305 9.55 9.53
550 11.74 12.22
580 12.10 12.08
433 13.69 13.53
467 13.82 14.59
398 13.84 14.21
421 13.07 14.52
339 13.03 14.12
1 31 32 362 366 11.68 11.44
2 36 37 485 466 13.47 12.59
3 51 35 551 443 10.80 12.66
4 39 47 509 609 13.05 12.96
5 39 36 497 461 12.74 12.81
0.95 0.97 7.87 7.38 11.10 12.20
0.92 1.87 7.06 13.70 12.15 11.76
0.97 1.15 7.76 8.44 11.54 12.44
1.12 1.21 8.72 9.45 11.71 11.56
1.13 0.97 8.87 7.62 11.59 11.77
0.75 0.90 6.12 7.61 11.50 10.95
0.92 1.37 7.33 11.04 11.62 11.03
1.43 1.16 11.62 8.71 10.91 12.16
1.03 0.66 10.74 6.89 8.53 8.88
1.33 1.22 11.30 10.00 10.41 11.00
0.85 1.15 6.99 9.48 11.26 10.94
0.86 1.44 6.26 10.62 12.84 12.09
1.32 1.16 9.56 7.92 12.50 13.44
0.77 0.96 5.59 6.78 13.06 13.25
0.93 0.93 7.08 6.41 12.15 13.59
0.81 0.67 6.19 4.72 12.23 13.46
0.65 0.72 5.52 6.28 11.03 10.72
0.92 0.92 6.80 7.30 12.56 11.68
0.92 1.20 8.53 9.48 9.88 11.46
0.74 0.94 5.70 7.22 12.31 12.02
1.23 0.97 9.66 7.59 11.51 11.83
a Significance at the 1% level (dead implants/pregnant female).
December 1973 31during week 3 at the dose level of 75 mg/kg is performed on a weekly basis and the para-
was not reproduced at 150 mg/kg (Table 12). meters of total and living implants are ex-
It should be noted that here again, no signifi- amined simultaneously with dead implants/
cant reduction was observed in either the to- pregnant female. In addition, this compound
tal or living implants/pregnant female at any was not active in any test for mutagenic po-
dose level during the test. The investigator is tential including the host-mediated and in
thus not mislead when the statistical analysis vivo cytogenetic assays.
Table 7. Experimental inconsistency, experiment 42, dose level 7.5 mg/kg, oral.
Number Total Tot. impl. Dead impl. % Total live Live impl.
pregnant implants Preg. fem. Preg. fem. Dead impl. impl. Preg. fem.
Week C T C T C T C T C T C T C T
1 44 32 514 383 11.68 11.97 0.98 0.88 8.37 7.31 471 355 10.70 11.09
2 41 46 508 576 12.39 12.52 0.95 0.85 7.68 6.77 469 537 11.44 11.67
3 48 50 595 611 12.40 12.22 1.15 1.12 9.24 9.17 540 555 11.25 11.10
4 45 39 600 499 13.33 12.79 1.18 1.00 8.83 7.82 547 460 12.16 11.79
5 46 38 624 545 13.57 14.34 1.13 1.00 8.33 6.97 572 507 12.43 13.34
6 39 53 494 653 12.67 12.32 1.21 1.06 9.51 8.58 447 597 11.46 11.26
7 39 42 515 542 13.21 12.90 0.72 1.57 5.44 12.18 487 476 12.49 11.33
8 44 41 572 543 13.00 13.24 1.16 1.17 8.92 8.84 521 495 11.84 12.07
Table 8. Significance levels, dose level 7.5 mg/kg.
Significance level
Dead impl. Live impl. Tot. impl.
Week Preg. fem. Preg. fem. Preg. fem.
1 0.10+ 0.10+ 0.10+
2 0.10+ 0.10+ 0.10+
3 0.10+ 0.10+ 0.10+
4 0.10+ 0.10+ 0.10+
5 0.10+ 0.10+ 0.10+
6 0.10+ 0.10 0.10
7 0.01' 0.10 0.10+
8 0.10+ 0.10+ 0.10+
a Weeks with significance at the 1% level.
Table 9. Experimental inconsistency, experiment 42, dose level, 75 mg/kg, oral.
Number Total Tot. impl. Dead impl. % Total live Live impl.
pregnant implants Preg. fem. Preg. fem. Dead impl. impl. Preg. fem.
Week C T C T C T C T C T C T C T
1 44 39 514 487 11.68 12.49 0.98 0.67 8.37 5.34 471 461 10.70 11.82
2 41 43 508 571 12.39 13.28 0.95 1.00 7.68 7.53 469 528 11.44 12.28
3 48 39 595 501 12.40 12.85 1.15 1.46 9.24 11.38 540 444 11.25 11.38
4 45 42 600 539 13.33 12.83 1.18 1.17 8.83 9.09 547 490 12.16 11.67
5 46 35 624 466 13.57 13.31 1.13 1.37 8.33 10.30 572 418 12.43 11.94
6 39 48 494 606 12.67 12.62 1.21 0.85 9.51 6.77 447 565 11.46 11.77
7 39 46 515 608 13.21 13.22 0.72 1.09 5.44 8.22 487 558 12.49 12.13
8 44 37 572 483 13.00 13.05 1.16 0.78 8.92 6.00 521 454 11.84 12.27
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Significance levels
Dead impl. Live impl. Tot. impl.
Week Preg. fem. Preg. fem. Preg. fem.
1 0.10+ 0.10+ 0.10+
2 0.10+ 0.10+ 0.10+
3 0.01 a 0.10+ 0.10+
4 0.10+ 0.10+ 0.10+
5 0.05 b 0.10+ 0.10+
6 0.10+ 0.10+ 0.10+
7 0.10+ 0.10+ 0.10+
8 0.10+ 0.10+ 0.10+
a Weeks with significance at the 1% level.
t'Weeks with significance at the 5% level.
Table 11. Experimental inconsistency, experiment 42, dose level, 150 mg/kg, oral.
Number Total Tot. impl. Dead impl. - -- % Total live Live impl.
pregnant implants Preg. fem. Preg. fem. Dead impl. impl. Preg. fem.
Week C T C T C T C T C T C T C T
1 44 31 514 371 11.68 11.97 0.98 0.97 8.37 8.09 471 341 10.70 11.00
2 41 49 508 607 12.39 12.39 0.95 0.94 7.68 7.58 469 561 11.44 11.45
3 48 40 595 485 12.40 12.12 1.15 0.98 9.24 8.04 540 446 11.25 11.15
4 45 38 600 483 13.33 12.71 1.18 0.95 8.83 7.45 547 447 12.16 11.76
5 46 49 624 671 13.57 13.69 1.13 1.10 8.33 8.05 572 617 12.43 12.59
6 39 43 494 544 12.67 12.65 1.21 0.79 9.51 6.25 447 510 11.46 11.86
7 39 46 515 620 13.21 13.48 0.72 1.07 5.44 7.90 487 571 12.49 12.41
8 44 37 572 478 13.00 12.92 1.16 1.27 8.92 9.83 521 431 11.84 11.65
Table 12. Significance levels, dose level 150 mg/kg.
Significance levels
Dead impl. Live impl. Tot. impl.
Week Preg. fem. Preg. fem. Preg. fem.
1 0.10+ 0.10+ 0.10+
2 0.10+ 0.10+ 0.10+
3 0.10+ 0.10+ 0.10+
4 0.10+ 0.10+ 0.10+
5 0.10+ 0.10+ 0.10+
6 0.10+ 0.10+ 0.10+
7 0.10+ 0.10+ 0.10+
8 0.05 0.10+ 0.10+
Weeks with significance at 5% level.
Effect of Dose Level
The qualitative pharmacologic action of
drugs must be considered when choosing
dose levels for D-L experiments. Drugs such
as anesthetics and tranquillizers have such
pronounced pharmacologic activity that ex-
cessive dose levels can produce marked temp-
erature reductions and an inability to mate
for several days following a single admin-
istration. An example of this kind of over-
dosage is shown in Figure 2. Here, 10°C
degree reductions in body temperature were
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FIGURE 2. Effect of triflupromazine on body temperature.
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mutagenic activity (7, 8). Clearly, such re-
ductions must reduce the overall metabolism
of the test animal and therefore influence
the metabolism of the drug. Levels of drug
used in mutagenicity assessments should be
chosen so as not to produce anorexia, seda-
tion, or other exaggerated pharmacological
effects (9).
Conclusions
In interpreting D-L data, the need for
demonstrating a statistically significant and
reproducible effect in the same stage of
spermatogenesis cannot be over emphasized.
In order to achieve consistent analyses, the
degree of variability in important paramet-
ers of dead, living and total implants per
pregnant female has to be firmly established
for each strain of mouse employed. The
statistical model utilized should include a
transformation to reduce the effect of differ-
ing variances which occur in dead and total
implants per pregnant female. Also, test
results obtained during a specific stage of
spermatogenesis should be compared to a
control regression computed across the en-
tire 8 weeks of testing. A dose response
curve obtained during the active period of
dominant lethality will provide additional
evidence of compound activity. Data from
D-L testing should be correlated and com-
pared to other assessments of mutagenic
potential such as the host-mediated and cyto-
genetic assays before applying the label of
mutagen. Finally, the dosage regimen em-
ployed should not seriously alter the normal
physiological processes of the test animal.
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